A liver transplant becomes necessary when the liver is damaged beyond its ability to repair itself and no other treatment can restore its function. This can happen gradually over months or years from chronic disease, or it can happen suddenly in a matter of days from acute injury. The most common path to transplant is cirrhosis, where healthy liver tissue is progressively replaced by scar tissue until the organ can no longer filter toxins, produce essential proteins, or regulate metabolism.
Chronic Liver Disease: The Most Common Reason
The vast majority of liver transplants follow years of chronic damage that eventually leads to cirrhosis. Several conditions can cause this, and many people live with early-stage liver disease for a long time before the damage becomes severe enough to warrant transplant evaluation.
Fatty liver disease tied to metabolic factors (now called MASLD, and its more severe inflammatory form, MASH) has risen dramatically as a transplant indication. In the late 1990s, it accounted for just 0.1% of liver transplants. By 2005, that number had climbed to 3.5%. Today, MASH is the second leading cause of liver transplant waitlisting in the United States overall, the primary cause in women, and the top indication for transplant in adults over 65. This surge closely tracks rising rates of obesity and type 2 diabetes.
Viral hepatitis, particularly hepatitis B and hepatitis C, has historically been the leading driver of transplant. Hepatitis C causes slow, progressive scarring over decades, and many people don’t know they’re infected until significant damage has occurred. Effective antiviral treatments developed in the last decade have reduced new transplant listings from hepatitis C considerably, but people whose livers were already severely scarred before treatment still need transplants.
Alcohol-related liver disease remains a major cause. Heavy, prolonged alcohol use inflames the liver repeatedly, and over time the organ scars irreversibly. Transplant programs typically require a sustained period of abstinence and a commitment to ongoing support before listing a patient, though policies vary by center.
Autoimmune and Genetic Conditions
The body’s own immune system can attack the liver in several distinct ways. Autoimmune hepatitis occurs when immune cells target liver tissue directly. Primary biliary cholangitis and primary sclerosing cholangitis both damage the bile ducts inside the liver, leading to bile buildup, inflammation, and eventually cirrhosis. Together, these three autoimmune liver diseases account for roughly 15% of liver transplants in the U.S. and about 25% in Europe.
Inherited conditions also play a role. Hemochromatosis causes the body to absorb too much iron, which deposits in the liver and damages it over time. Wilson disease leads to a buildup of copper in the liver. Both are treatable if caught early, but if the diagnosis comes too late or the disease progresses despite treatment, transplant may be the only option.
Liver Cancer
Liver cancer, specifically hepatocellular carcinoma, is a common reason for transplant because it often develops in livers that are already cirrhotic. In these cases, removing just the tumor isn’t practical since the remaining liver is too damaged to sustain the body. Replacing the entire organ treats both the cancer and the underlying disease at once.
Not everyone with liver cancer qualifies. Under the Milan criteria, which most transplant programs use, a patient can have a single tumor no larger than 5 centimeters (about 2 inches) in diameter, or two to three tumors each 3 centimeters or smaller. These limits exist because transplant outcomes are significantly better when the cancer hasn’t spread extensively. Some patients with tumors slightly beyond these limits may undergo treatment to shrink them enough to qualify, a process called downstaging.
Acute Liver Failure
Acute liver failure is rarer but far more urgent. Unlike chronic disease, which unfolds over years, acute failure means the liver shuts down within days or weeks in someone who previously had a healthy organ. These patients often go to the top of the transplant waiting list because without a new liver, death can follow within days.
The most common cause of acute liver failure in the United States is acetaminophen (Tylenol) overdose. This can happen from a single massive dose or from repeatedly taking slightly more than recommended over several days, especially in combination with alcohol. Other triggers include reactions to certain medications, herbal supplements, viral infections like hepatitis A or B, and rare conditions where the liver’s blood supply is suddenly cut off.
Why Children Need Liver Transplants
In children, the reasons for transplant look quite different. The leading cause is biliary atresia, a condition present from birth where the bile ducts inside or outside the liver are blocked or absent. Without functioning bile ducts, bile builds up and progressively destroys the liver. Most infants undergo a surgical procedure called the Kasai operation shortly after diagnosis to restore some bile flow, but many still develop cirrhosis over the following months or years.
Children with biliary atresia who progress toward liver failure often show signs well before the transplant itself: severe malnutrition, failure to grow, fat-soluble vitamin deficiencies, and in some cases metabolic bone disease that leads to fractures from minimal impact. When aggressive nutritional support can no longer sustain the child or the liver’s complications become unmanageable, transplant evaluation begins. Other pediatric causes include inherited metabolic diseases and, rarely, liver tumors.
How the Waiting List Works
Once a transplant team determines you need a new liver, you’re placed on a national waiting list managed by the United Network for Organ Sharing (UNOS). Your position isn’t first-come, first-served. Instead, priority is determined primarily by medical urgency, using a scoring system called MELD 3.0.
The MELD score estimates how likely a patient is to die within 90 days without a transplant. It’s calculated from blood tests measuring bilirubin (a marker of liver function), creatinine (kidney function), blood clotting ability, sodium levels, and albumin (a protein the liver produces). The updated MELD 3.0 formula also accounts for sex, correcting a documented disparity where women were previously underscored relative to their actual mortality risk. The update correctly reclassified nearly 9% of patients who had died on the waitlist to a higher priority tier, giving similar patients a meaningfully better chance at receiving an organ.
Beyond the score, allocation also considers distance from the donor hospital (shorter transport times improve outcomes) and whether the recipient is a child, since pediatric patients receive additional priority.
Living Donor Transplants
Because the liver can regenerate, it’s possible to transplant a portion of a living person’s liver into a recipient. The donor’s remaining liver and the transplanted portion both regrow to near-normal size within weeks. This option can significantly shorten wait times, which matters when a patient is deteriorating.
Living donors must be between 18 and 60 years old, in good physical and mental health, with a BMI under 32 and a blood type compatible with the recipient. They’re screened for heart disease, kidney disease, cancer, hepatitis, active infections, and substance abuse. The donation must be entirely voluntary, free from any pressure or financial incentive. Donors also need a reliable support system for recovery, which typically involves several weeks away from work and physical activity.
Survival After Transplant
Liver transplant outcomes have improved steadily and are now approaching pre-pandemic levels. According to the Scientific Registry of Transplant Recipients, mortality after a deceased-donor liver transplant is 6.8% at one year, meaning about 93% of recipients survive their first year with a new liver. At five years, roughly 80% are still alive. At ten years, the survival rate is about 64%. These are national averages, and individual outcomes depend on the underlying condition, the patient’s overall health at the time of surgery, and how well the body accepts the new organ.
After transplant, recipients take immunosuppressive medications for life to prevent their immune system from attacking the new liver. This requires regular blood work and ongoing follow-up, but most transplant recipients return to normal daily activities within a few months of surgery.